ESC 365 - Residual atherosclerotic cardiovascular disease risk in statin-treated adults: the multi-ethnic study of atherosclerosis

ESC Premium Access

Residual atherosclerotic cardiovascular disease risk in statin-treated adults: the multi-ethnic study of atherosclerosis

Session: Are we ever going to get to lipid goals?

Topic: Epidemiology, lipids

Speaker: Doctor N. Wong (Irvine, US)

Event: ESC Congress 2016

Congress Presentation

Add to my library

About the speaker

Doctor Nathan Wong

University of California at Irvine, Irvine (United States of America)

7 presentations

0 follower

6 more presentations in this session

Improvement of LDL-cholesterol goal attainment in high-risk patients in Europe and Middle East between 2008/09 and 2013/14 - Results of DYSIS and DYSIS II CHD

Speaker: Doctor A. Gitt (Ludwigshafen, DE)

Statin use and dose by low-density lipoprotein cholesterol level in U.S. commercially insured patients with type 2 diabetes

Speaker: Doctor R. Rosenson (New York, US)

Do we reach the LDL-c goals in Familial hypercholesterolemiapatients under Eighteen Years Old? SAFEHEART (Spanish Familial Hypercholesterolemia Longitudinal Cohort Study) follow-up study

Speaker: Doctor A. Saltijeral Cerezo (Madrid, ES)

Still high prevalence of persistent lipid abnormalities among patients with ACS or stable CHD despite chronic statin therapy in 2014: results of DYSIS II ACS and CHD

Speaker: Doctor A. Gitt (Ludwigshafen, DE)

Modeling lipid-lowering therapy intensification in the real world: how many patients with atherosclerotic cardiovascular disease would need a PCSK9 inhibitor?

Speaker: Doctor C. Cannon (Boston, US)

Access the full session

Are we ever going to get to lipid goals?

Speakers: Doctor N. Wong, Doctor A. Gitt, Doctor R. Rosenson, Doctor A. Saltijeral Cerezo, Doctor A. Gitt...

About the event

ESC Congress 2016

27 August - 31 August 2016

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources